


Writing the Future

EMILY LEPROUST, PH.D., CEO and CO-FOUNDER



Legal Disclaimers



This presentation contains forward-looking statements. In particular, statements regarding future economic performance, finances, and expectations and objectives of management constitute forward-looking statements. Forward-looking statements can be identified by the fact that they do not relate strictly to historical facts and generally contain words such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. Although the forward-looking statements contained in this presentation are based upon information available at the time the statements are made and reflect management's good faith beliefs, forward-looking statements inherently involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements to differ materially from anticipated future results. Important factors that could cause actual results to differ materially from expectations include, among others: our estimates of the size of our market opportunity; our expectations regarding our ability to increase gene production, reduce turnaround times and drive cost reductions for our customers; and our ability to enter new markets. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the market and our market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of our business.



DNA is Changing the World

Synthetic DNA Is the Future



Chemicals Sustainability Food Food Security Therapeutics Health **Diagnostics** Precision Medicine

Data Storage Preserving Heritage









AACGCGCAGACGAC AACGCGGCAGACGAG ATCCGAGCTAGCTACGAG ATTACGATCGACTAGCAGGAG GCTTACAGCAGCAGGATGAGC GCGATGAGCAGCTAGG TCAGCAGTCTACTA

Arzeda.





VANDERBILT UNIVERSITY






->> ancestry



EPFL W




Writing the Future

Our silicon-based DNA synthesis platform is fueling a world of applications




Miniaturization 10³⁻⁶ less volume of required reagents



Throughput 20M oligos/month capacity




Low cost Driving adoption



Large and Expanding Addressable Market






Strong Customer and Order Growth



Customers YoY growth % 82% 1,305 151% 717 195% 286 97 FY 2016 FY 2017 FY 2018 FY 2019


Orders





Quarterly Revenue Growth





Revenue (\$M)

Strong Revenue Growth and Increasing Gross Margin






Revenue


	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020E*
Gross Profit (\$M)	(\$7.2)	(\$13.3)	(\$6.8)	\$7.0	—
Gross Margin %	(300%)	(123%)	(27%)	13%	32%
Net Operating Loss (\$M)	(\$43.7)	(\$58.5)	(\$70.6)	(\$107.7)	(\$103) - (\$106)

* Guidance provided on December 10, 2019.




Twist Synthetic Biology





Synthetic Bio: Largest Selection of DNA Offered






Innovative Online Ordering

Ch	ange Veo	tor 🝷 🕇 Flanks	Coptimize 🗎 🕇 Gen	es + Cust	com Vector		Q	PRICING	SUMMARY ()	
#		NAME 🔸	SEQUENCE	BP	VECTOR	SCORE ()	PRICE	NAME	QTY	COST
1		gene-001	ACTCGACTGACTAGC	1264	Select Vector 🔹	•	\$113.76	Easy Genes Cloning Fee		\$2,376.00 \$1,300.00
2		gene-002	ACTCGACTGACTAGC	1014	Select Vector 🔹	٠	\$91.26	DELIVERY FORMAT		
3		gene-003	ACTCGACTGACTAGC	978	Select Vector 🔻	٠	\$88.02	 Plate: 96 Well, Horizontal Tube Edit 		
4		gene-004	ACTCGACTGACTAGC	848	Select Vector 🔻	۲	<u>Fix it</u>			
5		gene-005	ACTCGACTGACTAGC	1200	Select Vector 🔹	•	\$108.00	Total		\$3,676
6		gene-006	ACTCGACTGACTAGC	1124	Select Vector 💌	•	\$101.16	Cr	eckout	
7		gene-007	ACTCGACTGACTAGC	1200	Select Vector 💌	٠	<u>Fix it</u>			
8		gene-008	ACTCGACTGACTAGC	1087	Select Vector 💌	•	\$97.83			
9		gene-009	ACTCGACTGACTAGC	1200	Select Vector 🔻	•	\$108.00			

Synthetic Bio: Why We Win







We Deliver

- High quality DNA
- Competitive turnaround
- Affordability
- Fast throughput
- Unique customer experience
- Innovation

Synthetic Bio: Proof Points FY19



"

1000+ Customers

8B Bases shipped

288K Genes shipped

98% Orders via ecommerce




"

Case Study

P3 PANDEMIC PREVENTION PLATFORM

Rapid response to help medical workers fight viral diseases in the field



Twist delivered hundreds of genes in 9 business days for first DARPA sprint


Twist's very high-throughput platform allowed us to quickly and efficiently examine thousands of possible antibodies in order to select the best results faster than ever before. – Robert Carnahan

Synthetic Bio: Investing in Growth



Ecommerce-centric Velocity Sales GTM

- Growing sales team
- Expanding digital marketing
- Leveraging new product offerings




Source: BCC Research, Markets and Markets Report, internal company estimates

Targeted Sequencing

- is Powering New Applications
- Liquid biopsy
- Rare disease
- Oncology
- Population genetics



Twist NGS Delivers Superior Uniformity in Double-Stranded DNA



NGS: Broad Offering with Expanding Capabilities



Today

Human Core Exome Kit


Library Prep Kits

Custom Panels

Fixed Panels Human RefSeq Pan-Viral Mouse Exome

Fast Hyb & Wash Kit

Universal Adapters



NGS: Why We Win

Low Cost per Sample



Fast Throughput*

High DNA to 2x uniformity 8-10 20 hours sequencer drives lower weeks faster R&D in 1 day costs Test Sequencing Cost Hybridization ~4 weeks 50% Build less 5 hours Enrichment Kit Design Others TWIST Others TWIST TWIST Others

Rapid Customization

Illustrative models.

* Includes pooling 1 & 2, pre-hybridization, hybridization, binding, wash steps, amplification, purification, target environment QC, and NGS prep

NGS: Proof Points FY19



Exciting Use Cases 265 **Customers shipped** BROAD 36 in production Liquid biopsy **Degraded DNA** 2 **Blueprint OEM** partners -> ancestry Genetics SNP microarray conversion SNP Rare disease


| TWIST BIOSCIENCE 21


NGS: Investing in Growth



Solution Selling GTM


- Growing sales team
- Adding OEM partners






Twist Antibody Drug Discovery





Discovering Bio-Betters and Hard-to-Drug Targets





Bio-Betters

High Diversity, High Quality Molecules

- Affinity (pM)
- Immunogenicity
- Half-life
- Expression •
- Druggability


Solubility

Hard-to-Drug Targets

Leveraging technology to develop novel therapeutics for promising targets

GPCR Development Candidate: TBO1-3 is Potent GLP1R Antagonist






Potential application for rare diseases such as severe hypoglycemia

Pipeline of Functional Monoclonal Antibodies





GPCR TARGET	INDICATION		
ADORA2A	Cancer		
CRTH2	Asthma / inflammation		
CXCR4	Cancer		
CXCR5	Asthma / inflammation		
FSHR	Infertility		
GLP1R	Diabetes / rare metabolic diseases		
V2R	Cancer		

We are optimizing these leads and leveraging our platform for partnering discussions

Biopharma Collaborations



	LakePharma The Biologics Company	PANDION THERAPEUTICS	SCHRÖDINGER	Undisclosed
Focus	Co-marketing Twist services to their customers	Optimization of bispecific antibodies for autoimmune and inflammatory disease	Technology collaboration	Optimization of therapeutics
Economics	Shared economics	Per project	Collaboration on commercial opportunities	Per project

Twist Data Storage




Recovered from Lunar Orbiter 1 Tapes



DNA for **Archival Storage of Digital Information** GACGGAPermanenceCATCAT TAGCAGCGC Density GCAC GATCAT GAGC Random access(AGC ATCCCCUniversal format CTAC A A A G T A

Data Storage in DNA: How It Works



DNA Data Storage Non-Dilutive Funding

TWIST SELECTED as DNA SYNTHESIS PROVIDER UNDER THE INTELLIGENCE ADVANCED RESEARCH PROJECT AGENCY (IARPA)


	Collaborators	
Georgia Research Tech Institute	UNIVERSITY of WASHINGTON	

- Twist will receive up to \$9.15M
- Additional \$5.5 million slated to bolster DNA synthesis through new chip design, commercial implementation at Twist
- Significantly reduce the size, weight and power required for archival data storage
- Synthesize enough DNA per day to allow the cost of storing digital data to be as low as \$1/gigabyte
 - Ultimate Twist goal: Drive cost down to \$100/terabyte
- Bolster DNA synthesis through new chip design

I A R P A NON-DILUTIVE FINANCING

DNA Data Storage Roadmap





Delivering on Our Plan





T W I S T BIOSCIENCE


Writing the Future

Large, growing markets **Platform** for writing DNA on silicon **Portfolio** of high growth businesses **Differentiated** value proposition High, consistent revenue growth Track record of execution and innovation



Appendix





Experienced Management Team





Emily LeProust, PhD President, CEO Co-founder



Bill Banyai, PhD SVP, Advanced Development, GM Data Storage Co-founder



Bill Peck, PhD CTO Co-founder



Jim Thorburn CFO



Aaron Sato CSO Twist Biopharma



Patrick Finn, PhD Chief Commercial Officer



Patrick Weiss



Paula Green VP Human Resources



Mark Daniels Chief Legal Officer, Chief Ethics and Compliance Officer, SVP and Secretary



Martin Kunz SVP Operations